Phibro Animal Health Corporatio

Valuation Analysis

About the Company

Phibro Animal Health Corporatio en bref

Phibro Animal Health Corporatio (PAHC) is currently trading at 27,77 € with a market capitalization of 1,1 Md €. The trailing P/E ratio stands at 13.67x, with a forward P/E of 9.52x. The 52-week range spans from 20,55 € to 52,38 €; the current price is 47% below the yearly high. Year-over-year revenue growth stands at +10.3%. The net profit margin stands at 6.35%.

💰 Dividende

Phibro Animal Health Corporatio pays an annual dividend of 0,42 € per share, representing a yield of 1.51%. The payout ratio stands at 20.6%.

📊 Avis des analystes

5 analystes évaluent Phibro Animal Health Corporatio (PAHC) au consensus : Conserver. L'objectif de cours moyen est de 39,75 €, soit un potentiel de +43.17% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 33,13 € à 50,56 €.

Phibro Animal Health Corporatio : la thèse d'investissement en détail

Phibro Animal Health Corporatio (PAHC) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 10.3% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Return on equity of 30.34% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

Le scénario baissier

The debt-to-equity ratio of 217.97% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valorisation en contexte

The EV/EBITDA multiple of 8.53x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 9.52x is meaningfully below the trailing 13.67x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 43.17% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (6.22%), higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Phibro Animal Health Corporatio?

Compare top-rated brokers — low fees, trusted providers, fully regulated.